Bicycle Therapeutics Plc (BCYC)
3.45
-0.24
(-6.50%)
USD |
NASDAQ |
Nov 12, 16:00
3.445
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Enterprise Value : -280.85M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -280.85M |
| November 11, 2026 | -268.71M |
| November 10, 2026 | -268.71M |
| November 09, 2026 | -264.67M |
| November 06, 2026 | -272.76M |
| November 05, 2026 | -279.33M |
| November 04, 2026 | -267.20M |
| November 03, 2026 | -269.72M |
| November 02, 2026 | -272.25M |
| October 30, 2026 | -270.23M |
| October 29, 2026 | -262.14M |
| October 28, 2026 | -259.11M |
| October 27, 2026 | -264.16M |
| October 26, 2026 | -270.73M |
| October 23, 2026 | -275.79M |
| October 22, 2026 | -271.24M |
| October 21, 2026 | -274.78M |
| October 20, 2026 | -273.26M |
| October 19, 2026 | -276.55M |
| October 16, 2026 | -280.34M |
| October 15, 2026 | -273.26M |
| October 14, 2026 | -277.81M |
| October 13, 2026 | -271.75M |
| October 12, 2026 | -263.15M |
| October 09, 2026 | -258.60M |
| Date | Value |
|---|---|
| October 08, 2026 | -262.65M |
| October 07, 2026 | -266.69M |
| October 06, 2026 | -263.66M |
| October 05, 2026 | -252.54M |
| October 02, 2026 | -284.38M |
| October 01, 2026 | -275.28M |
| September 30, 2026 | -269.22M |
| September 29, 2026 | -310.97M |
| September 28, 2026 | -307.94M |
| September 25, 2026 | -309.20M |
| September 24, 2026 | -306.94M |
| September 23, 2026 | -313.49M |
| September 22, 2026 | -306.94M |
| September 21, 2026 | -311.97M |
| September 18, 2026 | -310.97M |
| September 17, 2026 | -309.46M |
| September 16, 2026 | -311.47M |
| September 15, 2026 | -309.96M |
| September 14, 2026 | -298.88M |
| September 11, 2026 | -300.39M |
| September 10, 2026 | -301.90M |
| September 09, 2026 | -293.08M |
| September 08, 2026 | -284.27M |
| September 04, 2026 | -278.22M |
| September 03, 2026 | -281.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 508.24M |
| DBV Technologies SA | 574.77M |
| Cellectis SA | 71.36M |
| Akari Therapeutics Plc | 4.334M |
| Biodexa Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.47M |
| Revenue (Quarterly) | 34.04M |
| Total Expenses (Quarterly) | 44.51M |
| EPS Diluted (Quarterly) | -0.1497 |
| Gross Profit Margin (Quarterly) | 96.85% |
| Profit Margin (Quarterly) | -30.77% |
| Earnings Yield | -58.94% |
| Normalized Earnings Yield | -58.94 |